---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-000676"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:31:31.837579+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine settles arbitration with Myeloid for $13.5M payment

## Summary
- Company to pay Myeloid $13.5M to resolve two arbitration proceedings related to former research collaboration.
- Settlement includes mutual covenants and release of all claims between parties.
- Arbitrations previously disclosed in Q3 2023 Form 10-Q.
- Agreement dated January 4, 2024, entered into between Prime Medicine and Myeloid.

## SEC filing metadata
- accession: 0001628280-24-000676
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828024000676/0001628280-24-000676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828024000676/prme-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-000676
- JSON: https://secwatch.observer/filing/0001628280-24-000676.json
- Plain text: https://secwatch.observer/filing/0001628280-24-000676.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.